QR Code

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia

Rosaria Di Lorenzo1, Alice Brogli21Department of Mental Health, AUSL-MODENA, Presidio Psichiatrico di Diagnosi e Cura 1, NOCSAE, Baggiovara, Modena, Italy; 2School of Specialization in Psychiatry, University of Modena e Reggio Emilia, Modena, ItalyAbstract: Olanzapine long-acting injection (OLAI) is...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Rosaria Di Lorenzo, Alice Brogli
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2010
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/b7f92fe5a5164c52bd42c81a2c87c99e
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
par: Ascher-Svanum H, et autres
Publié: (2014)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
par: JP Lindenmayer
Publié: (2010)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
par: Ciudad A, et autres
Publié: (2013)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
par: An, et autres
Publié: (2015)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
par: Louz&atilde; M, et autres
Publié: (2011)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
par: Zhao Y, et autres
Publié: (2013)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
par: Katagiri H, et autres
Publié: (2018)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
par: Anand E, et autres
Publié: (2016)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
par: Alphs L, et autres
Publié: (2013)

Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients
par: Torres-Llenza V, et autres
Publié: (2018)

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
par: Mario Louz&atilde;, et autres
Publié: (2010)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
par: Sugawara N, et autres
Publié: (2019)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
par: Adel Gabriel
Publié: (2010)

Risperidone long-acting injection: a review of its long term safety and efficacy
par: Michael K Rainer
Publié: (2008)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
par: Wani RA, et autres
Publié: (2015)

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
par: &Uuml;nsal C, et autres
Publié: (2013)

Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study
par: Strzelecki D, et autres
Publié: (2015)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
par: Pietrini F, et autres
Publié: (2019)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
par: Yang F, et autres
Publié: (2018)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
par: Wani RA, et autres
Publié: (2015)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
par: Montemagni C, et autres
Publié: (2016)

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
par: Giorgio L Colombo, et autres
Publié: (2008)

Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
par: Katagiri H, et autres
Publié: (2018)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
par: Suzuki H, et autres
Publié: (2013)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
par: Gao K, et autres
Publié: (2013)

A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
par: Andor M, et autres
Publié: (2019)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
par: Takahashi M, et autres
Publié: (2012)

Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
par: Ann E Maloney, et autres
Publié: (2010)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
par: Citrome L, et autres
Publié: (2019)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
par: Sliwa JK, et autres
Publié: (2012)

Emerging treatments in the management of bipolar disorder &ndash; focus on risperidone long acting injection
par: Wissam El-Hage, et autres
Publié: (2010)

Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile
par: Zolezzi M, et autres
Publié: (2021)

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?
par: Montgomery W, et autres
Publié: (2014)

Once-monthly paliperidone injection for the treatment of schizophrenia
par: Delia Bishara
Publié: (2010)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
par: Ohnishi T, et autres
Publié: (2021)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
par: Natalia N. Petrova, et autres
Publié: (2020)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
par: Sajatovic M, et autres
Publié: (2018)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
par: Citrome L
Publié: (2018)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
par: Okazaki K, et autres
Publié: (2017)